Evidence map›Paper›PMID 42782035›Full record

ArticleJACC. Case reports2026

Transthyretin Amyloidosis Due to a Rare TTR Val142del Deletion With Relatively Early Clinical Manifestations.

Cristhian Espinoza Romero, Kevin De Paula Morales, Christiane Espirito Santo, Guilherme Dos Santos Ferreira, Alan Silva Martins, Bruno Vaz Kerges Bueno, Fabio Fernandes

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cristhian Espinoza RomeroInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil. Electronic address: cristhian.153@hotmail.com.
Kevin De Paula MoralesInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil.
Christiane Espirito SantoInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil.
Guilherme Dos Santos FerreiraInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil.
Alan Silva MartinsInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil.
Bruno Vaz Kerges BuenoInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil.
Fabio FernandesInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHereditary transthyretin amyloidosis shows marked phenotypic heterogeneity. In-frame deletions at codon 142 are exceedingly rare, and their cardiac expression remains poorly characterized. CASE SUMMARY: A 62-year-old man presented with progressive neuropathy, autonomic dysfunction, weight loss, and recurrent syncope. Multimodality imaging demonstrated concentric hypertrophy with preserved ejection fraction, apical sparing on strain, diffuse late gadolinium enhancement with increased extracellular volume, and grade III uptake on 99mTc-pyrophosphate scintigraphy. Monoclonal gammopathy was excluded. Genetic testing identified a heterozygous the transthyretin p.Val142del deletion. Autonomic testing confirmed orthostatic hypotension with impaired chronotropic response. Heart failure therapy and tafamidis led to symptomatic improvement. Cascade screening identified 2 asymptomatic carriers. DISCUSSION: Unlike the common Val142Ile substitution, this deletion appears associated with earlier penetrance and multisystem involvement. TAKE-HOME MESSAGES: Rare transthyretin deletions may cause aggressive hereditary transthyretin amyloidosis. Early recognition and family screening are essential.

Indexed as

amyloidosisautonomic nervous system diseasesfamilialgenetic screeningmutationtransthyretin

Identifiers

PMID42782035
PMCPMC13616557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.